Q1 Earnings Estimate for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Leerink Partnrs lowered their Q1 2025 earnings estimates for Quanterix in a report issued on Monday, March 17th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.69) per share for the quarter, down from their previous estimate of ($0.58). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Separately, Canaccord Genuity Group lowered their target price on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday.

Quanterix Trading Down 0.3 %

Shares of Quanterix stock opened at $7.22 on Thursday. Quanterix has a 12 month low of $6.30 and a 12 month high of $24.87. The stock has a 50 day moving average of $8.18 and a 200 day moving average of $10.84. The firm has a market cap of $278.14 million, a PE ratio of -6.81 and a beta of 1.34.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The company had revenue of $35.16 million during the quarter, compared to analysts’ expectations of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%.

Institutional Investors Weigh In On Quanterix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new position in shares of Quanterix during the 3rd quarter valued at approximately $258,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Quanterix during the third quarter valued at $500,000. Intech Investment Management LLC purchased a new stake in shares of Quanterix in the third quarter valued at $170,000. Algert Global LLC lifted its holdings in shares of Quanterix by 75.9% in the 3rd quarter. Algert Global LLC now owns 137,833 shares of the company’s stock worth $1,786,000 after acquiring an additional 59,496 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Quanterix by 112.6% during the 3rd quarter. FMR LLC now owns 30,242 shares of the company’s stock worth $392,000 after purchasing an additional 16,020 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.